What is the management strategy for a patient with symptomatic mitral stenosis, possibly with a history of atrial fibrillation or rheumatic fever?

Management of Symptomatic Mitral Stenosis

For symptomatic patients with severe mitral stenosis (valve area ≤1.5 cm²), percutaneous mitral commissurotomy (PMC) is the first-line intervention when valve morphology is favorable, while those with unfavorable anatomy require surgical valve replacement or repair. 1

Initial Diagnostic Assessment

Echocardiography is the cornerstone for diagnosis and severity assessment. 1

• Measure mitral valve area by planimetry (the reference standard), with severe stenosis defined as ≤1.5 cm² 1, 2
• Assess mean transmitral gradient (severe typically ≥10 mmHg) and diastolic pressure half-time (≥150 ms indicates severe disease) 1, 2
• Evaluate pulmonary artery systolic pressure, as elevation >50 mmHg at rest mandates intervention even in asymptomatic patients 1, 3
• Perform transesophageal echocardiography (TEE) before any intervention to exclude left atrial thrombus 1, 3
• Calculate Wilkins score to assess valve morphology and suitability for PMC (score <8 suggests favorable anatomy for PMC; >10 suggests need for surgery) 4

Medical Management (Temporizing Measures Only)

Medical therapy alone in symptomatic severe mitral stenosis leads to poor outcomes, with 0-15% 10-year survival if intervention is not performed. 5 Medical therapy serves only to stabilize patients before definitive intervention:

• Diuretics for pulmonary congestion and peripheral edema 1, 3, 2
• Beta-blockers as first-line for heart rate control, particularly critical in atrial fibrillation to prolong diastolic filling time 1, 6, 3, 2
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) or digoxin as alternatives for rate control 1, 3, 2
• Avoid prolonged medical therapy alone, as this causes irreversible pulmonary hypertension and right heart failure 3

Anticoagulation Strategy

Vitamin K antagonists (warfarin) with target INR 2.0-3.0 are mandatory in specific high-risk situations; direct oral anticoagulants (DOACs) are contraindicated in mitral stenosis. 1, 3, 2

Indications for anticoagulation:

• Atrial fibrillation (regardless of CHA₂DS₂-VASc score) 1, 3, 7
• History of systemic embolism 1, 2
• Left atrial thrombus on echocardiography 1, 2
• Dense spontaneous echo contrast in left atrium 1, 2
• New-onset atrial fibrillation (requires immediate anticoagulation due to high thromboembolic risk) 6, 7

Indications for Intervention

Intervention is indicated for:

Symptomatic Patients (Class I Indication)

• NYHA class II-IV symptoms with valve area ≤1.5 cm² 1, 3, 2
• Symptoms occurring at low exercise levels despite medical optimization 6

High-Risk Asymptomatic Patients

• Pulmonary artery systolic pressure >50 mmHg at rest 1, 6, 3
• New-onset atrial fibrillation 1, 6, 3
• History of systemic embolism or dense spontaneous contrast in left atrium 1
• Need for major non-cardiac surgery 1, 3
• Desire for pregnancy 1, 3

Equivocal Symptoms

• When symptoms are discordant with resting hemodynamics, perform exercise echocardiography or stress testing 1
• Intervention indicated if exercise reveals mean gradient >15 mmHg, pulmonary artery pressure >60 mmHg, or pulmonary wedge pressure >25 mmHg 1

Choice of Intervention

Percutaneous Mitral Commissurotomy (PMC)

PMC is first-line for patients with:

• Favorable valve morphology (Wilkins score <8, minimal calcification, no significant mitral regurgitation, symmetric commissural fusion) 1, 2, 4
• Absence of left atrial thrombus on TEE 1, 3
• Less than moderate mitral regurgitation 1

PMC may be considered even with suboptimal anatomy if:

• Patient is high surgical risk or has surgical contraindications 1
• No unfavorable clinical characteristics present 1

Surgical Intervention

Surgery (open commissurotomy or valve replacement) is indicated for:

• Unfavorable valve morphology (Wilkins score >10, heavy calcification, significant subvalvular fusion, calcification of both commissures) 1, 2, 4
• Moderate or severe mitral regurgitation 1, 4
• Contraindications to PMC 1
• Failed prior PMC 1
• Concomitant cardiac surgery needed 1

Valve repair is preferred over replacement when feasible, especially in patients in sinus rhythm. 1

Critical Pitfalls to Avoid

• Never use DOACs instead of warfarin in mitral stenosis with atrial fibrillation – this is not guideline-supported and increases thromboembolic risk 3, 7
• Never proceed with PMC without TEE to exclude left atrial thrombus – this can cause catastrophic embolic events 1, 3
• Avoid vasopressors like midodrine – increased afterload reduces cardiac output and worsens pulmonary congestion 6
• Do not delay intervention in symptomatic severe stenosis – prolonged medical management leads to irreversible pulmonary vascular disease and right ventricular failure 3, 5
• Maintain strict heart rate control perioperatively – tachycardia is the primary trigger for acute decompensation 6

Monitoring Strategy

• Symptomatic patients on medical therapy require frequent monitoring with clinical assessment and echocardiography 3
• Asymptomatic severe mitral stenosis: echocardiography every 2-3 years (ESC) or every 3-5 years (ACC/AHA) 1, 3, 2
• Very severe stenosis or borderline hemodynamics: yearly monitoring 1, 2
• Monitor for development of atrial fibrillation, pulmonary hypertension, or symptom progression 2